Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.
复制标题
DOI：
10.1155/2012/419348
复制
发表时间：
2012
影响因子：
1.4
通讯作者：
Uemura H
中科院分区：
文献类型：
--
作者：
De Velasco MA;Uemura H
从识别导致人类前列腺癌进展的遗传和表观遗传变化中获得的知识现在正被用于开发功能相关的翻译模型。GEM(基因修饰小鼠)模型正在开发中，以包含与人类前列腺癌相关的相同分子缺陷。单倍体功能不全在前列腺癌中很常见，PTEN纯合缺失与晚期疾病密切相关。在本文中，我们讨论了PTEN基因敲除小鼠的进化以及PTEN与其他基因改变在肿瘤发生发展中的协同作用。此外，我们将概述使这些模型成为个性化药物开发中的关键角色的关键点，作为靶标和生物标记物开发和验证的潜在工具，以及药物发现的模型。
Knowledge gained from the identification of genetic and epigenetic alterations that contribute to the progression of prostate cancer in humans is now being implemented in the development of functionally relevant translational models. GEM (genetically modified mouse) models are being developed to incorporate the same molecular defects associated with human prostate cancer. Haploinsufficiency is common in prostate cancer and homozygous loss of PTEN is strongly correlated with advanced disease. In this paper, we discuss the evolution of the PTEN knockout mouse and the cooperation between PTEN and other genetic alterations in tumor development and progression. Additionally, we will outline key points that make these models key players in the development of personalized medicine, as potential tools for target and biomarker development and validation as well as models for drug discovery.